Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Aminocaproic acid
Drug ID BADD_D00106
Description An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.
Indications and Usage For use in the treatment of excessive postoperative bleeding.
Marketing Status approved; investigational
ATC Code B02AA01
DrugBank ID DB00513
KEGG ID D00160
MeSH ID D015119
PubChem ID 564
TTD Drug ID D0FD0H
NDC Product Code 59285-019; 69766-054; 0517-9120; 0517-9191; 72205-049; 47621-310; 60687-529; 69238-1637; 69539-161; 69680-116; 80005-128; 46438-0641; 54288-151; 60687-739; 0404-9812; 69680-115; 70377-104; 76055-0030; 17478-447; 49411-050; 80005-129; 65571-0025; 70966-0010; 31722-035; 42799-054; 49411-052; 0409-4346; 62559-225; 69238-1596; 73216-110; 71052-265; 17478-768; 59651-573; 60687-724; 66689-330; 70377-102; 70377-103; 80005-130; 17478-769; 73216-111; 0904-7165; 72572-015; 49411-051; 51672-4226; 52817-815
UNII U6F3787206
Synonyms Aminocaproic Acid | 6-Aminohexanoic Acid | 6 Aminohexanoic Acid | epsilon-Aminocaproic Acid | epsilon Aminocaproic Acid | 6-Aminocaproic Acid | 6 Aminocaproic Acid | Capralense | Capramol | Caproamin | Caprocid | Hexalense | CY-116 | CY 116 | CY116 | Epsamon | Epsikapron | Hemocaprol | Amicar | Caprolest
Chemical Information
Molecular Formula C6H13NO2
CAS Registry Number 60-32-2
SMILES C(CCC(=O)O)CCN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Agranulocytosis01.02.03.001---
Anaphylactic reaction10.01.07.001; 24.06.03.006--
Anaphylactic shock10.01.07.002; 24.06.02.004---
Anaphylactoid reaction10.01.07.003; 24.06.03.007---
Anxiety19.06.02.0020.000229%
Blood creatine phosphokinase increased13.04.01.001--
Blood urea increased13.13.01.006---
Bradycardia02.03.02.002---
Cerebrovascular accident17.08.01.007; 24.03.05.001--
Coagulopathy01.01.02.001---
Confusional state17.02.03.005; 19.13.01.001--
Delirium19.13.02.001--
Dermatitis23.03.04.002---
Diarrhoea07.02.01.001--
Discomfort08.01.08.003---
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.0070.000846%
Drug hypersensitivity10.01.01.0010.000777%-
Drug ineffective08.06.01.0060.000846%-
Dyspnoea02.11.05.003; 22.02.01.004--
Ejaculation disorder21.03.01.002--
Epistaxis22.04.03.001; 24.07.01.0050.001966%
Erythema23.03.06.0010.000229%-
Feeling abnormal08.01.09.014---
Flushing08.01.03.025; 23.06.05.003; 24.03.01.0020.000777%
Gastrointestinal pain07.01.05.005--
Gingival bleeding07.09.07.001; 24.07.02.0100.000343%-
Haemarthrosis12.04.03.001; 15.01.01.004; 24.07.01.0460.000686%-
Hallucination19.10.04.003--
Headache17.14.01.001--
The 1th Page    1 2 3    Next   Last    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene